72.60 0.00(0.00%) Date:

Gilead Sciences, Inc. (GILD): Baird Cuts Price Target On Possible Q3 Miss

Baird analysts lower third quarter estimates for Gilead based on HCV script data

Gilead Sciences,. (NASDAQ:GILD): RBC Expects Higher-Than-Expected Sovaldi-Epclusa Revenue

RBC Capital analysts weigh in on Gilead's possible game-changing third quarter